摘要
新型冠状病毒由于其极强的传染性和极高的突变性,目前已在全球范围内出现多种变异株,给各国的公共卫生系统带来了巨大的威胁和挑战,反复多次感染新型冠状病毒或在全世界成为流行趋势。与非肿瘤患者相比,淋巴瘤患者更易感染新型冠状病毒,预后较差,因此应高度重视对淋巴瘤患者合并新型冠状病毒感染(COVID-19)的临床管理。本文就淋巴瘤合并COVID-19患者的临床特征及目前临床管理策略进行综述,为该类患者的临床治疗提供参考。
Novel coronavirus has brought great threats to the people and challenges to the health systems around the world.Compared with general population,lymphoma patients are more vulnerable to novel coronavirus infection(COVID-19)and have poorer prognosis.So the clinical management of COVID-19 in lymphoma patients in more difficult and the great importance should be attached.This article reviews the clinical characteristics and current management strategies of lymphoma patients with COVID-19,to provide reference for the clinical treatment of lymphoma patients with COVID-19.
作者
党雪萍
侯淑玲
陈潘
王桂琴
陈艺卓
Dang Xueping;Hou Shuling;Chen Pan;Wang Guiqin;Chen Yizhuo(Department of Lymphatic Oncology,the Third Hospital of Shanxi Medical University(Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital),Taiyuan 030032,China)
出处
《中华临床感染病杂志》
CAS
CSCD
2023年第4期315-320,共6页
Chinese Journal of Clinical Infectious Diseases
